Table 1 Characteristics of included studies
Study | Type | Patients | Antibiotic administration | outcome | Length Following |
|---|---|---|---|---|---|
Wang et al. 2014 [19] | Series Cases | N = 109 Intraventricular/intrathecal administration plus Intravenous: 14 Only Intravenous: 95 | IV: Imipenem; Meropenem; Meropenem/colistin; Ceftazidime/cefepime; Ceftriaxone; trimethoprim / Sulfamethoxazole IT: Amikacin, Colistin, Gentamicin, | Mortality cure Re-infection | 1 year |
Chusri et al. 2017 [12] | Retrospective observational cohort | N = 33 Intraventricular/intrathecal administration plus Intravenous: 17 Only Intravenous: 16 | IV: Colistin IT: Colistin | Mortality Length of Stay Hospital cure | 30 days |
From Bonis et al. 2016 [13] | Series cases | N = 17 Intraventricular/intrathecal administration plus Intravenous: 9 Only Intravenous: 8 | IV: Colistin IT: Colistin | Mortality Length of Stay Hospital Cure Re-infection unfavorable prognosis | 90 days |
Rodriguez-Guardado et al. 2008 [16] | Retrospective observational cohort | N = 51 Intraventricular/intrathecal administration plus Intravenous: 21 Only Intravenous: 30 | IV: Colistin IT: Colistin | Mortality Length of Stay Hospital cure Re-infection | 90 days |
Fotakopoulos et al. 2016 [14] | Retrospective observational cohort | N = 34 Intraventricular/intrathecal administration plus Intravenous: 23 Only Intravenous: 11 | IV: Colistin IT: Colistin | Mortality Length of Stay Hospital cure | 90 days |
Moon et al. 2013 [15] | Retrospective observational cohort | N = 22 Intraventricular/intrathecal administration plus Intravenous: 10 Only Intravenous: 12 | IV: Colistin IT: Colistin | Mortality cure relapse | 30 days |
Shofty et al. 2016 [17] | Retrospective observational cohort | N = 50 Intraventricular/intrathecal administration plus Intravenous: 23 Only Intravenous: 27 | IV: Ampicillin / sulbactam, Piperaciline /tazobactam, Vancomycin, Gentamicin, Amikacin, Ceftazidime, Ceftriaxone, Merponem ITEM: Ampicilin / sulbctam, Piperaciline /tazobactam, Vancomycin, Gentamicin, Amikacin, Ceftazidime, Ceftriaxone, Meropenem | Mortality cure unfavorable prognosis | 30 days |
Tuon et al. 2010 [18] | Series cases | N = 22 Intraventricular/intrathecal administration plus Intravenous: 4 Only Intravenous: 18 | IV: Ampicillin / sulbactam, Piperacillin /tazobactam, Vancomycin, Gentamicin, Amikacin, Ceftazidime, Ceftriaxone, Meropenem ITEM: Ampicillin / sulbactam, Piperacillin /tazobactam, Vancomycin, Gentamicin, Amikacin, Ceftazidime, Ceftriaxone, Meropenem | Mortality cure unfavorable prognosis | 30 days |